José Medrano Laporte-rekin lankidetzan egindako argitalpenak (18)

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2011

  1. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

  2. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy

    Journal of Infectious Diseases, Vol. 203, Núm. 11, pp. 1629-1636

  3. Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance

    Journal of Viral Hepatitis, Vol. 18, Núm. 1, pp. 11-16

  4. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis

    Journal of Viral Hepatitis, Vol. 18, Núm. 8, pp. 542-548

2010

  1. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy

    Antiviral Therapy, Vol. 15, Núm. 6, pp. 881-886

  2. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection

    Journal of Infectious Diseases, Vol. 202, Núm. 8, pp. 1185-1191

  3. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV

    Clinical Infectious Diseases, Vol. 51, Núm. 10, pp. 1209-1216

  4. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649

  5. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C virus coinfected patients with prior nonresponse or relapse

    Journal of Acquired Immune Deficiency Syndromes, Vol. 53, Núm. 3, pp. 364-368

  6. Survival of HIV-infected patients with compensated liver cirrhosis

    AIDS, Vol. 24, Núm. 5, pp. 745-753

  7. Update on HIV and HCV coinfection

    Hot Topics in Viral Hepatitis, pp. 17-24

  8. Viral hepatitis and HIV co-infection

    Antiviral Research, Vol. 85, Núm. 1, pp. 303-315

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

  2. Hepatitis B in HIV patients: What is the current treatment and what are the challenges?

    Journal of HIV Therapy, Vol. 14, Núm. 1, pp. 13-18

  3. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir

    AIDS, Vol. 23, Núm. 6, pp. 689-696

  4. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

2008

  1. Risk for immune-mediated liver reactions by nevirapine revisited

    AIDS Reviews, Vol. 10, Núm. 2, pp. 110-115